Summary: New research indicates that people experiencing a first episode of psychosis who also have skin problems are more likely to face severe psychiatric outcomes, including higher rates of depression and suicidality. In a study of 481 individuals, those reporting dermatological symptoms such as rash or itching were more than three times as likely to report suicidal thoughts compared with those without skin symptoms.
Researchers propose that visible skin signs might serve as an early biological marker for poor psychiatric prognosis, similar to how certain blood tests can signal elevated risk for physical illnesses. The connection may reflect shared developmental and inflammatory pathways between the brain and the skin.
Key Findings
- Elevated suicidality: About 25% of patients with dermatological symptoms had suicidal thoughts or attempts, compared with 7% of patients without skin symptoms.
- Prevalence of skin symptoms: Among the 481 people studied after a first psychotic episode, 14.5% showed dermatological complaints. The prevalence was 24% in females and 9.8% in males.
- Potential early marker: Dermatological symptoms were linked with greater depression and worse overall well-being after four weeks of treatment, suggesting they could identify a subgroup at higher short-term risk.
This research was presented at the European College of Neuropsychopharmacology (ECNP) meeting in Amsterdam and could inform earlier, more personalized psychiatric care for patients at risk of poor outcomes.
The study followed 481 patients who were experiencing a first episode of psychosis — the initial occurrence of symptoms such as hallucinations, delusions, or loss of contact with reality. At baseline, 14.5% had dermatological symptoms including rash, itching, and photosensitivity. All participants received four weeks of antipsychotic treatment and were then reassessed across several mental health outcomes.
Lead researcher Dr Joaquín Galvañ (Instituto de Investigación Sanitaria Gregorio Marañón, Madrid) reported that patients presenting with skin conditions at the outset had significantly worse psychiatric outcomes at follow-up. “After four weeks of follow-up, patients with skin conditions experienced higher levels of depression and an increased risk of suicide,” he said. “Only 7% of patients without initial skin conditions reported suicidal thoughts or attempts, while roughly 25% of those with skin symptoms did.”
Dr Galvañ added that initial dermatological findings were also associated with poorer overall well-being at follow-up. He suggested that skin symptoms may signal a subgroup of first-episode psychosis patients with a more severe short-term trajectory who might benefit from early, tailored interventions.
The biological rationale for the link is not yet established, but the investigators note a compelling developmental connection: both the nervous system and the skin originate from the embryonic ectoderm and share inflammatory and signaling pathways. “Our working hypothesis is that common developmental origins and inflammatory mechanisms might underlie the association, but further research is required to confirm this,” Dr Galvañ said. He emphasized that this is the first study to identify this association specifically in psychosis and that replication and extension to other psychiatric diagnoses—such as bipolar disorder, ADHD, anxiety disorders, and major depression—are needed.
Professor Eric Ruhe (Radboud University, the Netherlands), commenting independently, described the finding as an intriguing association that warrants further investigation. He noted that because both skin and brain cells derive from the same embryonic tissue, exploring the relationship could be valuable both diagnostically and mechanistically. “This association might even allow researchers to use cultured skin cells to test and tailor treatments,” he observed. Professor Ruhe was not involved in the study.
Key Questions Answered:
A: Patients with skin problems at the time of a first psychotic episode were substantially more likely to experience depression and suicidal thoughts during short-term follow-up.
A: Both tissues develop from the embryonic ectoderm and share inflammatory and signaling pathways that could influence psychiatric vulnerability.
A: Dermatological symptoms could help clinicians identify high-risk patients early, enabling prompt, personalized interventions aimed at reducing depression and suicidality.
About this mental health research news
Author: Tom Parkhill
Source: European College of Neuropsychopharmacology (presented at the 38th ECNP Congress)
Contact: Tom Parkhill – European College of Neuropsychopharmacology
Image credit: Neuroscience News
Original research: Findings presented at the 38th ECNP Congress; further peer-reviewed publication and replication studies are needed to validate and extend these results.